GLP-1s Are Doing More Than You Think

Most people start a GLP-1 for one reason. They want to lose weight. That is a completely reasonable place to begin, and for most patients it is what happens.

But the research that has come out between 2023 and 2026 keeps pointing at something bigger. These medications interact with systems all over the body, not just fat tissue and appetite. The heart, the liver, the kidneys, the airway, the brain. Researchers are still mapping how far it goes.

A May 2026 review by Savas and colleagues put it plainly. GLP-1s look less like weight management tools and more like disease-modifying therapies, meaning drugs that change the underlying biology of a disease rather than just managing the number on a scale. That is a real shift in how the medical field talks about them, and the data behind it is worth a few minutes of your time.

The cardiovascular finding that changed the conversation

This is the one that moved the medical establishment.

The SELECT trial enrolled more than 17,000 adults who were overweight or obese and already had cardiovascular disease, but did not have type 2 diabetes. The question was simple. Does semaglutide reduce cardiac events in people who are not diabetic?

It does. Semaglutide cut the risk of major adverse cardiovascular events, meaning heart attack, stroke, and cardiovascular death, by roughly 20 percent. In the trial, 6.5 percent of patients on semaglutide hit a primary cardiovascular endpoint compared with 8 percent on placebo. That gap sounds small on a page. Spread across a population, it is thousands of events that never happen.

In June 2025 the American College of Cardiology issued a formal statement noting that semaglutide and tirzepatide have proven substantially more effective at reducing cardiovascular risk than lifestyle changes alone, with fewer risks than procedure-based interventions. The ACC encouraged clinicians to consider GLP-1s as first-line options for eligible patients. That is a meaningful move away from prior guidance, which treated them as secondary. The FDA also approved oral semaglutide for cardiovascular risk reduction in patients with type 2 diabetes, the first oral GLP-1 cleared for a cardiovascular indication.

A 2026 analysis in the Journal of the American College of Cardiology found similar risk reduction signals in broader populations, not only in people with established heart disease. Dedicated trials there are still running.

Sleep apnea: a drug that can replace a machine

Obstructive sleep apnea affects an estimated 30 million adults in the United States, and most of them are undertreated. CPAP works. The problem is that a lot of people cannot stick with it.

In two major clinical trials, tirzepatide significantly improved sleep apnea in patients with obesity. After a year of treatment, patients averaged 27.4 to 30.4 fewer apnea events per hour. For context, moderate sleep apnea is defined as 15 to 30 events per hour. A drop of that size can move someone from moderate to mild, or out of the clinical range altogether.

Part of that is mechanical. Less weight means less tissue compressing the airway during sleep. But researchers also suspect GLP-1 receptors in the upper airway muscles and in the brainstem respiratory centers play a role, which would mean the effect goes beyond what weight loss alone explains. That part is still being worked out.

Liver disease: an old problem, a new option

MASH, short for metabolic dysfunction-associated steatohepatitis and formerly called NASH, is a progressive fatty liver disease that affects roughly 1 to 5 percent of the US population. It can advance to cirrhosis and liver failure. Until very recently there was almost nothing approved to treat it.

In August 2025 the FDA approved semaglutide for MASH in adults with moderate to advanced liver scarring, using the accelerated pathway reserved for serious conditions. The approval came out of the ESSENCE trial, which showed semaglutide beat placebo on both primary endpoints: resolution of steatohepatitis without worsening fibrosis, and improvement in fibrosis without worsening steatohepatitis.

This is not a downstream weight loss effect. Researchers believe GLP-1 receptors in the liver directly reduce inflammatory signaling and lipid accumulation, independent of how much fat a patient loses.

Kidney disease: the approval nobody talked about

In January 2025 the FDA approved semaglutide for chronic kidney disease in patients with type 2 diabetes. That is a separate indication from both the weight loss and the cardiovascular approvals, and it got very little attention.

The supporting data showed semaglutide reduced the risk of kidney disease progression and kidney-related death. Those are outcomes that have historically been very hard to move with medication. The mechanism appears to be part hemodynamic, meaning reduced pressure inside the kidney's filtering units, and part direct anti-inflammatory action through GLP-1 receptors in kidney tissue. Same pattern as the liver. The drug is doing something active in the organ itself.

The brain and addiction: the strangest frontier

The most surprising research area right now is addiction.

The same reward-dampening effect that quiets food noise appears to reduce the pull of other addictive substances. A randomized trial by Hendershot and colleagues published in 2025 enrolled 48 adults with alcohol use disorder. Participants got either semaglutide up to 1.0mg weekly or placebo for about nine weeks.

Outside the lab, participants drank on roughly the same number of days. What changed was how much. They had fewer drinks per session and more weeks without heavy drinking. Some participants also cut back on cigarettes. The researchers suspect the mechanism mirrors what happens with food. GLP-1 receptor activation in reward centers makes alcohol less motivationally compelling. The desire to drink does not disappear. The urge to overdo it gets quieter.

Active research is now looking at nicotine, opioid use disorder, and compulsive gambling. The common thread is reward circuitry. If GLP-1 receptors modulate dopamine signaling broadly, the therapeutic reach goes well past what these drugs were designed for.

The muscle problem, and what to do about it

The good news list needs one honest caveat, and it deserves more than a footnote.

Rapid weight loss on a GLP-1 can come with 15 to 25 percent lean muscle loss alongside the fat. Muscle is metabolically active, it is critical for keeping weight off, and it is increasingly tied to longevity. Losing a lot of it while you lose fat quietly undercuts many of the benefits you started the medication for.

The fix is not complicated, but it is not passive either. A November 2025 review in Frontiers in Clinical Diabetes and Healthcare pulled together the evidence on GLP-1s and exercise. Long-term weight maintenance is significantly more successful when structured exercise is part of the plan. Stopping treatment without that foundation usually leads to regain. Exercise gives you an independent mechanism to hold onto muscle and keep results.

What the current evidence supports:

• Adequate protein, with most providers recommending 1.2 to 1.6 grams per kilogram of body weight per day
• Structured resistance training at least twice a week
• Treating both as part of the protocol, not optional extras

The drug is powerful. What you do alongside it determines whether the results last.

What "disease-modifying" actually means

Calling GLP-1s disease-modifying rather than weight loss drugs is not a marketing flourish. It changes how you think about who should take them and for how long.

A disease-modifying therapy does not just manage symptoms. It changes the biological trajectory of the disease. Statins are the classic example. They lower LDL, but more importantly they reduce cardiovascular events in a way that goes beyond the cholesterol number itself. GLP-1s appear to work the same way, doing something biologically real to cardiac tissue, liver tissue, kidney tissue, and brain tissue that is not simply a consequence of a smaller body.

That also explains why stopping tends to reverse most of the benefit. If the medication is actively modulating biology rather than just enabling weight loss, then stopping means that modulation stops too, and biology goes back to what it was.